Kunal Mahajan: Lipoprotein(a) and LDL-C Target Attainment in ACS Patients
Kunal Mahajan, Director and Chief Interventional Cardiologist at Himachal Heart Institute, shared a post on X about a recent article he and his colleagues co-authored, adding:
“Happy to share our study in the Journal of Clinical Lipidology.
In ACS patients treated with triple oral lipid-lowering therapy, lipoprotein(a) increased significantly after ACS, and higher baseline lipoprotein(a) predicted failure to achieve low-density lipoprotein cholesterol less than fifty milligrams per deciliter at one month.”
Title: Changes in Lipoprotein(a) and Their Association With LDL-C in ACS Patients Treated with Triple Oral Lipid-Lowering Therapy
Authors: Kunal Mahajan, Nitin Mahajan, Jai Bharat Sharma, Surender Himral, Tanuj Bhatia, Deep Dutta
Read the Full Article on Journal of Clinical Lipidology
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 30, 2026, 01:52Javed Anees: DADA2 – When a Young Stroke Is More Than a Stroke
-
Sep 30, 2026, 01:51How a Venous Thrombus Becomes Revascularized – ISTH
-
Sep 29, 2026, 22:45Victor Agunyego: Paracetamol – The Most Common Drug We Underestimate
-
Sep 29, 2026, 22:42Nova Sinclair: Advancing the Future of Hematology – Meet Our 2027 Organizing Committee
-
Sep 29, 2026, 22:41Lorenz Räber: Intracoronary Imaging in PCI – Why, When, How, and Which Modality?
-
Sep 29, 2026, 22:31Selma Turkovic: Pleased to Deliver the Opening Presentation at Kingston Hospital
-
Sep 29, 2026, 22:31Miguel Teran: Ultrasound and Simulation in Arterial Blood Sampling
-
Sep 29, 2026, 22:28Mohammad Refaei: Navigating Your Career in Hematology From Training to Practice
-
Sep 29, 2026, 22:27Matteo Foschi: 10 Clinical Pearls for Antithrombotic Therapy in Secondary Stroke Prevention